Patients with NPM1 mutation and CBF AML had excellent outcomes, with 2-year OS of 88% and 100%, respectively; patients without either of these lesions (n = 22) had poorer survival (P < .001; Figure 5D). This evidence concerns the gene CEBPZ and acute myeloid leukemia.